Show simple item record

dc.contributor.authorFolayan, Morenike Oluwatoyin
dc.contributor.authorConway, Magda
dc.contributor.authorRusso, Carolyn
dc.contributor.authorDiniz, Nilza
dc.contributor.authorJafta, Lungile P
dc.contributor.authorSam-Agudu, Nadia A
dc.contributor.authorBernays, Sarah
dc.contributor.authorSantana, Victor M
dc.contributor.authorEpps, Carla
dc.contributor.authorTurner, Mark A
dc.date.accessioned2022-05-24T12:41:10Z
dc.date.available2022-05-24T12:41:10Z
dc.date.issued2022-05-20
dc.identifier.urihttp://hdl.handle.net/10713/18991
dc.description.abstractThe concept of health equity-the attainment of the highest possible level of health for all members of society-requires equitable access to all aspects of healthcare, including pediatric drug development. However, many communities are under-represented in pediatric drug development programs. Barriers to participation include geographic, economic, racial/ethnic bias, legal, cultural, linguistic, and other factors. While there is no "one size fits all" approach to addressing these barriers, community engagement and collaboration is recognized by the Centers for Disease Control, the World Health Organization, and other global health organizations as a cornerstone for building a more equitable healthcare system. In this article, we will present case studies of stakeholder and community engagement in clinical research for rare diseases and other areas of healthcare, as examples of strategies and practices for actively involving under-represented communities and fostering their participation in pediatric drug development programs. These studies may serve as templates for facilitating equity in pediatric drug development from aspiration into operation.en_US
dc.description.urihttps://doi.org/10.1007/s43441-022-00410-3en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35596108/en_US
dc.language.isoenen_US
dc.publisherSpringer Natureen_US
dc.relation.ispartofTherapeutic Innovation & Regulatory Scienceen_US
dc.rights© 2022. The Author(s).en_US
dc.subjectAccessen_US
dc.subjectAdolescenten_US
dc.subjectChilden_US
dc.subjectDrug developmenten_US
dc.subjectEngagementen_US
dc.subjectHealth equityen_US
dc.subjectStakeholdersen_US
dc.titleHealth Equity in Pediatric Drug Development: Translating Aspiration into Operation.en_US
dc.typeArticleen_US
dc.identifier.doi10.1007/s43441-022-00410-3
dc.identifier.pmid35596108
dc.source.journaltitleTherapeutic innovation & regulatory science
dc.source.countrySwitzerland


This item appears in the following Collection(s)

Show simple item record